Abstract 278P
Background
The advent of trastuzumab deruxtecan has led to the creation of a new treatment criterion for low HER2 expression (HER2-low : HER2 IHC score of 1+ or 2+/ISH not amplified). Utilizing 40 years of detailed clinical data from our hospital, the study aimed to investigate clinicopathological factors and long-term prognosis in HER2-low and HER2-zero breast cancer.
Methods
A total of 4,810 early-stage breast cancer cases were operated on and followed up from 1981 to 2022 at our hospital. We analyzed HER2 expression status in tumor tissues, clinicopathological factors, and prognosis in 3,788 cases excluding stage 0 cases.
Results
HER2-low cases accounted for 48% (1,819/3,788) of all cases analyzed, while HER2-zero cases comprised 34% (1,280/3,788). Among HER2-low cases, 89% were hormone receptor (HR) positive, with 11% classified as triple-negative (TN) breast cancer. In contrast, 83% of HER2-zero cases were HR positive, while 17% exhibited TN. Notably, HER2-zero cases showed a higher proportion of TN compared to HER2-low cases.
Prognostic analysis showed that the HER2-low group exhibited significantly superior outcomes in both disease-free survival (DFS) and overall survival (OS) compared to the HER2-zero group (p=0.005, p
Conclusions
In early-stage breast cancer, HER2-low patients had a better prognosis than HER2-zero patients, suggesting that HER2 expression status may result in different outcomes due to different hormone receptor expression rates and sensitivity to drug therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Toyama: Non-Financial Interests, Personal and Institutional, Invited Speaker: Eli Lilly, Pfizer, Daiichi Sankyo, Chugai, Kyowa Kirin, Eisai; Non-Financial Interests, Personal, Invited Speaker: Taiho, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
334P - Cardiovascular events related to CDK4/6 inhibitors: A systematic review and safety meta-analysis of randomized controlled trials
Presenter: Louis Boismoreau
Session: Poster session 14
335P - First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid tumors
Presenter: Fengjuan Lin
Session: Poster session 14
336P - Determination of the most common hereditary mutations associated with breast cancer and ovarian cancer in the population of Ukrainian women
Presenter: Dmytro Nehrulia
Session: Poster session 14
337P - Is presence of molecular residual disease after pathologic complete response associated with relapse in inflammatory breast cancer?
Presenter: Jennifer Chen
Session: Poster session 14
338TiP - EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Presenter: Michail Ignatiadis
Session: Poster session 14
339TiP - A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)
Presenter: Theodoros Foukakis
Session: Poster session 14
351P - Abemaciclib plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial
Presenter: Giampaolo Bianchini
Session: Poster session 14
352P - Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03)
Presenter: Noor Wortelboer
Session: Poster session 14
353P - Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
Presenter: Robert Scheel
Session: Poster session 14